The influence of bromelain on platelet count and platelet activity in vitro

References

• Ota S, Horie K, Hagino F, Hashimoto C, Date H. Fractionation and some properties of the proteolytically active components of bromelains in the stem and the fruit of the pineapple plant. J Biochem 1972; 71: 817–830, (Tokyo)
   PubMed Web of Science ®Google Scholar
• Yamada F, Takahashi N, Murachi T. Purification and characterization of a proteinase from pineapple fruit, fruit bromelain FA2. J Biochem 1976; 79: 1223–1234, (Tokyo)
   PubMed Web of Science ®Google Scholar
• Taussig SJ, Batkin S. Bromelain the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol 1988; 22: 191–203
   PubMed Web of Science ®Google Scholar
• Lotz-Winter H. On the pharmacology of bromelain: an update with special regard to animal studies on dose-dependent effects. Planta Med 1990; 56: 249–253
   PubMed Web of Science ®Google Scholar
• Kelly GS. Bromelain: A literature review and discussion of its therapeutic applications. Altern Med Rev 1996; 1: 243–257
   Google Scholar
• Leipner J, Iten F, Saller R. Therapy with proteolytic enzymes in rheumatic disorders. BioDrugs 2001; 15: 779–789
   PubMedGoogle Scholar
• Masson M. Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice. MMW – Fortschritte der Medizin 1995; 113: 303–306
   Google Scholar
• Maurer HR. Bromelain: Biochemistry, pharmacology and medical use. Cellular and Molecular Life Sciences 2001; 58: 1234–1245
   PubMed Web of Science ®Google Scholar
• Taussig SJ, Nieper HA. Bromelain: Its use in prevention and treatment of cardiovascular disease – Present status. J IAPM 1979; 6: 139–150
   Google Scholar
• Heinicke RM, van der Wal L, Yokoyama M. Effect of bromelain (Ananase®) on human platelet aggregation. Experientia 1972; 28: 844–845
   PubMedGoogle Scholar
• Sano T, Yokoyama M. Inhibitory effect of proteolytic enzymes on platelet aggregation induced by ADP or thrombin. Experientia 1971; 27: 1179–1181
   PubMedGoogle Scholar
• Livio M, De Gaetano G, Donati MB. Effect of bromelain on fibrinogen level, prothrombin complex and platelet aggregation in the rat – A preliminary report. Drugs Exptl Clin Res 1978; 4: 49–53
   Google Scholar
• Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178–195
   PubMed Web of Science ®Google Scholar
• Michelson AD. Flow cytometry: A clinical test of platelet function. Blood 1996; 87: 4925–4936
   PubMed Web of Science ®Google Scholar
• Michelson AD, Barnard MR, Krueger LA, Frelinger AL, 3rd, Furman MI. Evaluation of platelet function by flow cytometry. Methods 2000; 21: 259–270
   PubMed Web of Science ®Google Scholar
• Hilberg T, Eichler E, Glaser D, Schmidt V, Gabriel HH. Platelet activity, reactivity and platelet-leukocyte conjugate formation before and after exhaustive or moderate exercise in patients with IDDM. Platelets 2004; 15: 101–108
   PubMed Web of Science ®Google Scholar
• Metzig C, Grabowska E, Eckert K, Rehse K, Maurer HR. Bromelain proteases reduce human platelet aggregationin vitro, adhesion to bovine endothelial cells and thrombus formation in rat vesselsin vivo. In Vivo 1999; 13: 7–12
   PubMed Web of Science ®Google Scholar
• Hirano K, Kanaide H. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb 2003; 10: 211–225
   PubMedGoogle Scholar
• Dubois C, Steiner B, Meyer Reigner SC. Contribution of PAR-1, PAR-4 and GPIbalpha in intracellular signaling leading to the cleavage of the beta3 cytoplasmic domain during thrombin-induced platelet aggregation. Thromb Haemost 2004; 91: 733–742
   PubMed Web of Science ®Google Scholar
• Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, Cattaneo M, Kunapuli SP. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 2002; 99: 3629–3636
   PubMed Web of Science ®Google Scholar
• Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74–78
   PubMed Web of Science ®Google Scholar
• Gachet C, Hechler B, Leon C, Vial C, Leray C, Ohlmann P, Cazenave JP. Activation of ADP receptors and platelet function. Thromb Haemost 1997; 78: 271–275
   PubMedGoogle Scholar
• Puri RN, Colman RW. ADP-induced platelet activation. Crit Rev Biochem Mol Biol 1997; 32: 437–502
   PubMed Web of Science ®Google Scholar
• Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994; 83: 404–414
   PubMedGoogle Scholar
• Ginsberg MH, Frelinger AL, Lam SC, Forsyth J, McMillan R, Plow EF, Shattil SJ. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb–IIIa with conformation-specific monoclonal antibodies. Blood 1990; 76: 2017–2023
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307–315
   PubMed Web of Science ®Google Scholar
• Selnick HG, Barrow JC, Nantermet PG, Connolly TM. Non-peptidic small-molecule antagonists of the human platelet thrombin receptor PAR-1. Curr Med Chem Cardiovasc Hematol Agents 2003; 1: 47–59
   PubMedGoogle Scholar
• De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 2001; 276: 4692–4698
   PubMed Web of Science ®Google Scholar